Fundraising Fox
/Companies
Sign in

AZTherapies

Boston, US · Founded 2011 · Delaware corporation · 2 known investors

Find your way into AZTherapies

Sign up to see every warm intro you have to AZTherapies

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AZTherapies team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Clinical biopharmaceutical company developing treatments for neurological conditions.

Biotech

Founders & leadership

AZTherapies was founded in 2011 by David R Elmaleh.

DR
David R ElmalehFounder

Board

KG
Keith GreenfieldBoard director
PC
Peter ContiBoard director
RT
Ronald TompkinsBoard director
JP
John PorterBoard director

Investors · 2

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$85.8M disclosed across 8 rounds · 2014–2020

▶$14.8MraisedSep 2020 · 59 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ContiDirector
  • George BehrakisDirector
  • Thierry PorteDirector
  • Brian BartlettExecutive Officer
  • Noah GottdienerDirector
  • Karen ReevesExecutive Officer
  • David TaftDirector
  • Gillian SandlerDirector
  • David ElmalehExecutive Officer, Director
  • Keith GreenfieldDirector
Offering amount
$35M
Amount sold
$14.8M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19MraisedJul 2019 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David R.. ElmalehExecutive Officer, Director
  • Robert S. WarrenExecutive Officer
  • Keith GreenfieldDirector
  • David TaftDirector
  • Ronald TompkinsDirector
  • Brian BartlettExecutive Officer
  • George T. BehrakisDirector
  • Gillian SandlerDirector
  • Karen ReevesExecutive Officer
  • Jay MohrExecutive Officer
  • Peter ContiDirector
Offering amount
$37.5M
Amount sold
$19M
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.6MraisedMay 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PorterDirector
  • Karen ReevesExecutive Officer
  • David R. ElmalehExecutive Officer, Director
  • Gillian SandlerDirector
  • Peter ContiDirector
  • Keith GreenfieldExecutive Officer, Director
  • Robert S. WarrenExecutive Officer
  • David TaftDirector
  • Ronald TompkinsDirector
Offering amount
$7.5M
Amount sold
$5.6M
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedOct 2018 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ronald TompkinsDirector
  • Peter ContiDirector
  • Gillian SandlerDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • David R. ElmalehExecutive Officer, Director
  • Keith GreenfieldExecutive Officer, Director
  • Karen ReevesExecutive Officer
  • David TaftDirector
Offering amount
$25.5M
Amount sold
$16.1M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedDec 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ronald TompkinsDirector
  • Peter ContiDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • Keith GreenfieldExecutive Officer, Director
  • David TaftDirector
  • David R. ElmalehExecutive Officer, Director
Offering amount
$6M
Amount sold
$1.6M
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.5MraisedNov 2017 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldExecutive Officer, Director
  • David R. ElmalehExecutive Officer, Director
  • David TaftDirector
  • Ronald TompkinsDirector
  • Robert S. WarrenExecutive Officer
  • Peter ContiDirector
  • John PorterDirector
Offering amount
$7.6M
Amount sold
$6.5M
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedFeb 2017 · 41 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldExecutive Officer, Director
  • Ronald TompkinsDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • Peter ContiDirector
  • David R. ElmalehExecutive Officer, Director
  • David TaftDirector
Offering amount
$20M
Amount sold
$16.1M
First sale
Nov 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedJan 2015 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldDirector
  • Peter ContiDirector
  • Ronald TompkinsDirector
  • David R ElmalehExecutive Officer, Director
  • John PorterDirector
Offering amount
$13M
Amount sold
$6.1M
Minimum investment
$25K
Proceeds to insiders
$150K
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does AZTherapies do?
Clinical biopharmaceutical company developing treatments for neurological conditions.
Who founded AZTherapies?
AZTherapies was founded by David R Elmaleh in 2011.
Who are AZTherapies's investors?
AZTherapies's investors include Catalytic Impact Foundation, Dolby Family Ventures.
How much funding has AZTherapies raised?
AZTherapies has disclosed $85.8M raised across 8 rounds.
Where is AZTherapies headquartered?
AZTherapies is headquartered in Boston, US.